FDA Approves Third Biosimilar to Trastuzumab

January 18, 2019

On January 18, the FDA approved trastuzumab-dttb (Ontruzant, Samsung Bioepis), a biosimilar to trastuzumab (Herceptin), for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.

Read the OncLive news coverage here.

Posted 1/18/19

Upcoming Events

Oncology

ACCC Oncology Reimbursement Meeting | St. Louis

In Person Meeting & NetworkingMay 13, 2026 at 8:00 AM CDT1335 South Lindbergh Boulevard, St. Louis, MO, USAHilton St. Louis Frontenac, St. Louis

Oncology

ACCC 43rd National Oncology Conference

In Person Conference & ConventionOctober 21, 2026 at 8:00 AM MDT450 Summer St, Boston, MA 02210Omni Boston Hotel at the Seaport, Boston

Oncology

RIOS 2026 Spring Symposium

In Person Conference & ConventionMay 9, 2026 at 11:00 AM EDT4 Richmond Square, Providence, RI 02906, USAWaterman Grille, Providence

Oncology

HSCO 2026 May Dinner Symposium

In Person Conference & ConventionMay 13, 2026 at 5:30 PM HST6600 Kalanianaʻole Highway suite 110, Honolulu, HI, USARoy's Restaurants – Hawaii Kai, Honolulu

Oncology

WSOS 2026 Laramie Meeting

In Person Conference & ConventionMay 20, 2026 at 5:30 PM MDT222 South 22nd Street, Laramie, WY, USAUniversity of Wyoming – Rochelle Gateway Center, Laramie

Oncology

IOS 2026 Welcome Reception

In Person Conference & ConventionMay 30, 2026 at 6:00 PM CDT1060 West Addison Street, Chicago, IL, USAWrigley Field, Chicago

Oncology

WAHO 2026 Welcome Reception

In Person Conference & ConventionMay 30, 2026 at 6:00 PM CDT1060 W Addison St, Chicago, IL, USAWrigley Field , Chicago

Oncology

WSOS 2026 Rock Springs Meeting

In Person Conference & ConventionJune 9, 2026 at 5:30 PM MDT1675 Sunset Dr, Rock Springs, WY, USAHoliday Inn Rock Springs, Rock Springs

Oncology

HSCO 2026 June Dinner Symposium

In Person Conference & ConventionJune 10, 2026 at 5:30 PM HST3660 Waialae Ave, Honolulu, HI, USA3660 On The Rise, Honolulu

Trending Now on
ACCCBuzz Blog

Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung Cancer

Small Cell SMASHERS was founded in 2023 as a patient-centered advocacy and education community designed to challenge long-standing narratives about small cell lung cancer and restore a sense of voice, connection, and hope for patients and their loved ones.

Partnering to Deliver Targeted Treatment: Fox Chase Cancer Center and Omniscope

ACCCBuzz spoke with Fox Chase Cancer Center to learn more about its partnership with Omniscope, a leader in advanced molecular profiling technology, in hopes of developing an assay that accurately predicts which patients will respond well to immunotherapy based on the presence of certain T-cell clones.

Innovation, Policy, and Partnership: Key Takeaways From the Inaugural ACCC Leadership Summit

On Friday, April 17, ACCC welcomed oncology leaders from around the country to Washington, DC for the inaugural ACCC Leadership Summit, a forum designed for executive-level decision-makers to engage in strategic dialogue, peer-to-peer exchange, and actionable insights at the highest level of oncology leadership.

Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions

During the HOPA 2026 annual conference, ACCC brought together a small group of oncology pharmacists for a practical, candid conversation about challenges with the implementation of bispecific antibodies that was deeply grounded in real-world experience and what it takes to operationalize care.

View All ACCCBuzz Blogs